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ABSTRACT: The dissolution and permeation of the cocrystals, Flufenamic acid – 
nicotinamide (FFA-NIC) and Flufenamic acid – theophylline (FFA-TP), have been 
investigated in the presence of two polymers, polyvinylpyrrolidone (PVP) and 
copolymer of vinyl pyrrolidone/vinyl acetate (PVP-VA), using a 
dissolution/permeation (D/P) system. It showed that the types and concentrations of 
the polymers and their interactions with the coformers had significant effects on the 
dissolution and permeation of the FFA cocrystals. The role of PVP as a stabilizing 
agent was not altered in spite of its interaction with the coformer of NIC or TP, which 
was supported by the proportional flux rate of FFA to the dissolution performance 
parameter (DPP). With an appropriate PVP concentration, the maximal flux rate of 
FFA could be obtained for a given FFA cocrystal. The situation was complicated in 
the presence of PVP-VA. The role of PVP-VA could change due to its association 
with the coformers, i.e., from a stabilizing agent to a solubilisation agent. In addition, 
PVP-VA reduced the flux rate of FFA contrasting to its DPP for FFA cocrystals. 
Finally, 1H NMR provided evidence regarding the molecular interactions between 
FFA, coformers and polymers at atomic level and gave insight into the mechanism 
underlying the supersaturated solution and subsequent permeation behaviour of the 
cocrystals.   
KEYWORDS: cocrystal, flufenamic acid, 1H NMR, polymer, dissolution, 
permeation  
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1. INTRODUCTION 
Over the last decade, pharmaceutical cocrystals have been studied extensively as 
potential tools to optimise the drug product performance, in particular for compounds 
with limited aqueous solubility/dissolution rates.1-3 However, the supersaturated 
solution generated by dissolution of the highly soluble cocrystals was 
thermodynamically unstable and the parent drug had a tendency of rapid 
precipitation.4-6 It was shown that the parent drug tended to precipitate directly onto 
the surface of the dissolving cocrystals during dissolution, acting as a coating layer to 
diminish the dissolution and solubility of the cocrystals.4, 5 In sight of this, inclusion 
of effective crystallisation inhibitors in the formulations have been explored to 
maintain the supersaturated conditions of API (active pharmaceutical ingredient).4, 6-11 
On one occasion, an excess use of coformer or micellar solubilisation decreased the 
solubility of cocrystals, leading to a lower degree of supersaturation and subsequent 
prevention of drug precipitation.7, 8 Maintaining supersaturated drug concentration 
was also achieved by introducing stabilizing agents in the formulation, that the 
equilibrium solubility of the drug was not enhanced but the nucleation and/or crystal 
growth of the drug were inhibited by the intermolecular interactions between the drug 
molecules and the stabilizing agents. Although polymeric crystallisation inhibitors 
have been widely used in amorphous solid dispersion formulations to stabilize the 
amorphous state of the drug substance and to maintain its supersaturated status in 
solution,12, 13 such studies have rarely been carried out in cocrystal based 
formulations.4, 9, 10, 14-16 The selection of a polymeric excipient in a cocrystal 
formulation seemed to be much more complicated than those used in the solid 
dispersion system because the inhibitory ability of the polymers could be undermined 
significantly by the competitions between the drug, the coformer and the polymer in 
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terms of hydrogen bondings.9 Furthermore, a dissolved polymer could alter the 
dissolution of the cocrystals and subsequently affect its inhibitory ability on the 
precipitation of the parent drug.4  
For orally administered solid dosage forms of a drug compound, the elevation of 
drug concentration in the gastrointestinal (GI) tract did not always improve the 
absorption as the drug molecules have to permeate across the GI membrane. It was 
reported that, despite of an increased solubility due to the presence of co-solvent, 
micelle, cyclodextrin, hydrotropy and emulsifier, a reduced fraction of free drug for 
membrane permeation by drug encapsulation could eventually lead to very poor drug 
absorption.17-25 Therefore, the balance between the solubility and the permeability had 
to be optimised to achieve the maximal overall absorption of a poorly water soluble 
drug. The drug permeability of  an amorphous solid dispersion formulation was highly 
polymer dependent.20, 26-29  A few evidence showed that the cocrystals alone could 
alter both the solubility and the permeability of the APIs.30-32 Though it was not clear 
that, in a cocrystal based formulation, how the permeability of the parent drug was 
affected by additional polymeric excipients, some speculated that the interplay of the 
solubility and permeability was the determining factor for a successful formulation.  
Our previous investigations found that inclusion of the polymers of 
polyvinylpyrrolidone (PVP) and copolymer of vinyl pyrrolidone/vinyl acetate (PVP-
VA) altered the dissolution of cocrystals of flufenamic acid-nicotinamide (FFA-NIC) 
and flufenamic acid-theophylline (FFA-TP) and maintained the supersaturation of 
FFA in solution.33 In this work we pioneered a systematic examination of key 
processes occurred during cocrystal dissolution of FFA-NIC and FFA-TP in the 
absence and presence of PVP or PVP-VA at different concentrations to reveal the 
kinetics of drug supersaturation and permeation. The molecular structures of FFA 
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cocrystals and the monomer units of the polymers were shown in Table 1 and a 
detailed description could be found from previous work.4, 9, 34, 35 Simultaneous 
evaluations of the dissolution of FFA cocrystals in the absence and presence of PVP 
or PVP-VA as well as the permeation of FFA through a dialysis membrane were 
achieved using a dissolution/permeation (D/P) system (Fig. 1). The dialysis 
membrane modelled the intestinal epithelium. The D/P system represented a 
simplified permeation model for quantitative analysis because of the negligible effect 
of polymer on the membrane.28, 36, 37 And it had been proved to be a useful tool for 
examining the absorption of oral drugs after administration.36-41  In the D/P system, 
the powdered drug substances were applied to the donor compartment, which was 
filled with dissolution media in the absence or presence of the polymer at various 
concentrations, under nonsink conditions to evaluate the ability of the polymer to 
maintain the supersaturated drug solution. Meanwhile, the amount of FFA molecules 
permeated into the acceptor compartment, which was filled with the dissolution 
media, was monitored. The temperature of the whole D/P system was maintained at 
37°C using a circulating water bath. The molecular interactions of the FFA, coformers 
and polymers were analysed by one-dimensional proton nuclear magnetic resonance 
(1H NMR) spectroscopy. The 1H NMR analysis was conducted in low polarity solvent 
deuterated chloroform (CDCl3) solutions containing singular, binary and ternary 
components of FFA, coformers and polymers. The changes of the chemical 
environment surrounding the molecules would be reflected by the characteristic peak 
shifts in 1H NMR spectra and the molecular mobility would be reflected by the peak 
widths.42-51   
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2. MATERIALS AND METHODS 
2.1. Materials. Flufenamic acid form I (FFA), Nicotinamide (NIC) (≥99.5% 
purity), Theophylline (TP) (≥99.5% purity), Potassium dihydrogen phosphate 
(KH2PO4) and sodium hydroxide (NaOH) were purchased from Sigma-Aldrich 
(Dorset, UK). Plasdone K-29/32 (PVP) and Plasdone S-630 (PVP-VA) were gifts 
from Ashland Inc. (Schaffhausen, Switzerland). Methanol (HPLC grade) and 
acetonitrile (HPLC grade) were purchased from Fisher Scientific (Loughborough, 
UK) and used as received. Double distilled water was generated from a Bi-Distiller 
(WSC044.MH3.7, Fistreem International Limited, Loughborough, UK) and used 
throughout the study. Deuterated chloroform (CDCl3) was purchased from Goss 
Scientific Instruments Ltd (Crewe, UK).  
2.2. Methods. 
2.2.1. Preparation of 0.01M Phosphate Buffer Solution (PBS), pH 4.5. PBS solution 
(0.01M, pH 4.5) was used as the dissolution medium. It was prepared according to 
British Pharmacopeia 2010: 1.361g of potassium phosphate monobase was dissolved 
in double distilled water and the pH of the solution was adjusted to 4.5 using 1 M of 
sodium hydroxide solution. 
2.2.2. Preparation of FFA Cocrystals. As previously described,9 the cocrystals of 
FFA-NIC and FFA-TP were prepared with the solvent evaporation and the cooling 
crystallization methods, respectively. The formation of cocrystals was confirmed by 
Differential Scanning Colorimetry (DSC), Fourier Transform Infrared Spectroscopy 
(FTIR) and Powder X-ray Diffraction (PXRD). 
2.2.3. The Apparent Equilibrium Solubility Measurement for FFA in the Absence 
and Presence of Polymers and/or Coformers. To investigate the effect of coformers 
and/or polymers on the solubility of FFA, 20 mL of 0.01 M PBS (pH 4.5) was used as 
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the solvent to prepare the solutions of PVP or PVP-VA at concentrations of 200 
µg/mL, 500 µg/mL, 1000 µg/mL, 2000 µg/mL, 4000 µg/mL, 8000 µg/mL, 12000 
µg/mL and 16000 µg/mL. Appropriate amount of the powdered FFA crystals was 
then added to these solutions for the apparent equilibrium solubility test. The FFA 
crystals were slightly grounded by a mortar and pestle and passed through a 60 mesh 
sieve so that the particle size of the crystals was no more than 250 µm. The test was 
carried out for 24 h at a temperature of 37 ± 0.5°C with constant mixing at 150 r.p.m. 
The clear solution was then separated from the remaining solid by centrifugation 
(MSB 010.CX2.5 centrifuge, MSE Ltd, London, U.K.) at 13,000 r.p.m. for 1 min and 
the concentration of FFA was determined by High Performance Liquid 
Chromatography (HPLC). 
To investigate the combined effects of coformer and polymer on the solubility of 
FFA, the above series of PVP or PVP-VA solutions were added with NIC or TP at a 
concentration of 47.8 µg/mL or 71.1 µg/mL, respectively. The coformer concentration 
selected in the experiments was based on the flux rate experiments, which 1.43 mg of 
FFA-NIC and 1.64 mg of FFA-TP were corresponding to 47.8 µg/mL of NIC and 
71.1 µg/mL of TP, under the assumption of complete dissolving of the FFA 
cocrystals. An appropriate amount of the FFA crystals was then added to these 
solutions for the apparent equilibrium solubility test. 
2.2.4. The Dissolution and Permeation Measurements. The D/P system was used to 
evaluate the dissolution and permeation of cocrystals. It consisted of a donor and an 
acceptor compartment, which was separated by a regenerated cellulose membrane 
with a Molecular Weight Cut-Off (MWCO) of 6-8 KDa (Spectrum Labs Inc. Rancho 
Dominguez, CA 90220, USA) (Fig. 1). Either the donor or acceptor compartment has 
a capacity of 10 mL. The orifice diameter of the compartment was 0.9 cm, 
Page 9 of 44
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
corresponding to 0.671 cm2 surface area of the membrane. Like the FFA crystals, the 
crystalline substance used in this experiment were prepared to sizes that no bigger 
than 250 µm. 1 mg of single component crystals of FFA or cocrystals with equivalent 
amount of FFA were firstly added to the donor compartment and this was followed by 
the addition of 9 mL of 0.01 M PBS (pH 4.5) to the receptor compartment. 9 mL of 
0.01 M PBS (pH 4.5) in the absence or presence of PVP or PVP-VA (200 µg/mL, 
4000 µg/mL, and 16000 µg/mL) was then added to the donor compartment which 
contained the crystals. The temperature of the whole system was maintained at 37°C 
by a circulating water bath. 0.5 mL of the sample was withdrawn from the donor 
compartment at the time intervals of 5, 10, 15, 30, 60, 120 and 240 mins using a 
syringe and any volume change due to the withdrawal was immediately compensated 
with 0.01 M PBS (pH 4.5). The concentrations of FFA were then determined by 
HPLC.  
The dissolution performance parameter (DPP)52 was used to evaluate the dissolution 
of the FFA cocrystals, as detailed previously,4 and the dissolution of FFA crystals was 
used as the reference. The difference of the DPP of the FFA cocrystals measured in 
the absence and presence of PVP or PVP-VA would give indication of the effect of 
the polymers on dissolution and on the maintenance of drug supersaturation. 
The flux of a drug through the membrane, which was defined as the amount of drug 
crossing a unit area perpendicular to its flow direction per unit time t, was calculated 
using the following equation: 
() =
	

(	
)
                                                                      (1) 
where () was  the flux of a drug;  was the drug concentration (µg/mL) at ; 	 
was  the drug concentration (µg/mL) at ; V was the solution volume and A is the 
area of exposed membrane. 
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2.2.5. NMR Measurements. 1H NMR was used to identify the interactions between 
the drug, coformer and polymer in solution. The measurements were carried out with 
a Bruker AV400 NMR Spectrometer (Bruker UK Limited, Coventry, UK) and the 
same settings were used throughout the measurements: 64 scans with a relaxation 
delay of 1 s, a spectral of 8278Hz, a time domain of 32k data and analysing software 
Mestrenova V11.0 (Mestrelab Research, Escondido, CA 92027, USA). 
All the samples were prepared in deuterated chloroform (CDCl3) using the standard 
5 mm NMR tubes and the spectra of tetramethysilane (TMS) was used as an internal 
standard. Detailed measurements were shown in Table S1 in the Supporting 
Information, which included spectra of the singular component (FFA, NIC, TP, PVP, 
PVP-VA), the binary components (FFA/NIC, FFA/TP, FFA/PVP, FFA/PVP-VA, 
NIC/PVP, NIC/PVP-VA, TP/PVP, TP/PVP-VA) and the ternary components 
(FFA/NIC/PVP, FFA/NIC/PVP-VA, FFA/TP/PVP, FFA/TP/PVP-VA). 
To mimic a cocrystal system, the FFA and its coformers were included in the 
solution at 1:1 molar ratio. Three sets of concentrations were prepared for the 
simulated cocystal system: 215 µg/mL NIC/ 320 µg/mL TP and 500 µg/mL FFA; 430 
µg/mL NIC/640 µg/mL TP and 1000 µg/mL FFA; 2150 µg/mL NIC/3200 µg/mL TP 
and 5000 µg/mL FFA. For investigation of the effect of polymer on the simulated 
cocrystal system, PVP or PVP-VA was included in the solution at a concentration of 
200 µg/mL or 5000 µg/mL, respectively.   
2.2.6. High Performance Liquid Chromatography (HPLC) Analysis. The 
concentration of FFA, NIC or TP was determined by HEWLETT PACKARD series 
1100 automatic HPLC with a Luna@ Omega PS C18 100A LC column (5 µm, 150 × 
4.6 mm) (Phenomenex, Inc., Macclesfield, UK). The sample temperature was 
maintained at 40°C. The conditions used for measurements were listed in Table 2. 
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3. RESULTS 
3.1 Effects of Polymer and/or Coformer on the Equilibrium Solubility of 
FFA. The effects of polymer and/or coformer on the equilibrium solubility of FFA 
were shown in Fig. 2. The equilibrium solubility of FFA at 37°C measured in PBS 
was 9.0 ± 0.7 µg/mL. PVP had a moderate effect, which the solubility of FFA was 
slightly increased with the PVP concentration of 1000 µg/mL and it reached the 
maximum of 14.9 ± 1.0 µg/mL at the PVP concentration of 2000 µg/mL. In contrast, 
the effect of PVP-VA could be seen at the concentration of 1000 µg/mL and it 
became more prominent with the increase of the concentration. In fact, the solubility 
of FFA reached 17.2 ± 1.6 µg/mL at a PVP-VA concentration of 4000 µg/mL and 
37.6 ± 0.5 µg/mL at a PVP-VA concentration of 16000 µg/mL.  
Whereas the presence of NIC seemed to have no effect, the presence of TP at a 
concentration of 71.1 µg/mL increased the equilibrium solubility of FFA to 10.24 ± 
0.71 µg/mL. Neither NIC nor TP altered the equilibrium solubility of FFA in the 
solution containing PVP. In contrast, the presence of NIC or TP further enhanced the 
solubility FFA observed in solutions containing PVP-VA.  
3.2. Effect of Polymers on the Dissolution and Permeation of FFA Cocrystals. 
The dialysis membrane acted as a selective barrier for the substances to pass through 
based on their sizes. The MWCO of the dialysis membrane used in the study was 6-8 
KDa and it would thus allow the transfer of FFA, which has a molecular weight 
(MW) of 281 Da, from the donor compartment  
3.2.1. Dissolution and Permeation Performances of FFA, FFA-NIC and FFA-TP in 
PBS. Fig. 3 (a) showed the dissolution of FFA, FFA-NIC and FFA-TP obtained from 
the D/P system. It could be seen that FFA-NIC had the fastest dissolution and FFA 
reached its maximum concentration, 8.8 ± 0.2 µg/mL, within the first 5 min. After 
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that the FFA concentration measured for FFA-NIC gradually dropped and the 
minimum concentration, 7.5 ± 0.3 µg/mL, was obtained at 120 min. In contrast, the 
concentrations measured for FFA and FFA-TP slowly increased to the equilibrium 
solubility of FFA, 9.0 ± 0.3 µg/mL, at 60 min and remained that concentration 
afterwards. The quantitative comparison of DPPs4 were  shown in Fig. 4 (a), which 
FFA-NIC had a lower DDP than that of FFA and FFA-TP. 
Fig. 3 (b) showed the permeation of FFA, FFA-NIC and FFA-TP obtained from the 
D/P system. In the first 60 min, the gradually increased FFA concentrations measured 
for all three solids overlapped. After that, the concentrations of FFA measured at all 
three occasions increased steadily and FFA and FFA-TP had a slightly greater rate 
than that of FFA-NIC. This was in consistent with the mass flux rates shown in Fig. 4 
(b).  
3.2.2. Effect of PVP or PVP-VA on the Dissolution and Permeation of FFA, FFA-
NIC and FFA-TP. Fig. 5 demonstrated the effect of PVP on the dissolution of FFA, 
FFA-NIC and FFA-TP in the donor compartment and the subsequent permeation of 
FFA to the acceptor compartment. Both FFA-NIC and FFA-TP showed an enhanced 
dissolution in comparison to their parent drug FFA when PVP was added to the 
dissolution media.  A supersaturated state of FFA was observed for FFA-TP and FFA-
NIC in the dissolution media with PVP at 200 µg/mL, where the concentration of 
FFA reached 16.7 µg/mL for FFA-TP at 5 min and 12.2 µg/mL for FFA-NIC at 15 
min [Fig. 5(a1)]. The concentrations of FFA observed for FFA-NIC and FFA-TP were 
then gradually reduced to the parent drug’s solubility at the 60 min point [Fig. 5(a1)].  
Correspondingly, the presence of PVP increased the amount of FFA detected in the 
acceptor compartment to 1.23-fold for FFA-TP and 1.17-fold for FFA-NIC [Fig. 4 
(b)], but decreased the amount of FFA detected at the acceptor compartment by 15.4% 
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for the parent FFA [Fig. 5 (b1) and Fig. 4 (b)].  All these phenomena suggested that 
the inclusion of PVP in the dissolution media increased the dissolution and 
permeation of FFA cocrystals, whereas it slowed down the dissolution as well as the 
permeation of the parent FFA.  
When PVP was added to a concentration of 4000 µg/mL, the concentration of FFA 
detected in the donor compartment for FFA-TP reached 40 µg/mL at 15 min, which 
was approximately 4.5-fold of the solubility of FFA [Fig. 5 (a2)]. And the 
concentration of FFA detected for FFA-NIC at the same time was 23.6 µg/mL. These 
indicated that FFA-TP had a better dissolution than FFA-NIC. On the other hand, the 
concentration of FFA detected for FFA-NIC in the donor compartment quickly 
decreased to 19.5 µg/mL at 15 min and remained constant afterwards. In contrast, the 
concentration of FFA detected in the donor compartment for FFA-TP decreased 
slowly from 40 µg/mL and stabilized to 28.8 µg/mL after 60 min. Consequently, the 
DPP of FFA-TP was 228% higher than that of FFA and was 128% higher that of 
FFA-NIC [Fig. 4 (a)]. In accordance with these, the amount of FFA detected at the 
acceptor compartment increased by 1.69-fold in the case of FFA-TP and by 1.27-fold 
in the case of FFA-NIC [Fig. 5 (b2) and Fig. 4 (b)]. 
Interestingly, a further increased concentration of PVP to 16000 µg/mL diminished 
the dissolution of FFA-TP and FFA-NIC, as shown in Figs. 5 (a3) and Fig. 4 (a). The 
maximal concentration of FFA detected in the donor compartment was 27.5 µg/mL 
for FFA-TP and 19.7 µg/mL for FFA-NIC. Meanwhile, the amount of FFA permeated 
cross the membrane reduced significantly for FFA-TP and FFA-NIC [Fig. 5 (b3)]. 
And the flux rate of the FFA-TP was 0.62-fold of the FFA observed in 0.01 M PBS 
and 0.45-fold for the FFA-NIC [Fig. 5 (b3) and Fig. 4 (b)]. In addition, in comparison 
to those measured in PBS, 16000 µg/mL of PVP significantly slowed down the 
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dissolution of FFA [Fig. 5 (a3)], as demonstrated by a 9% reduction of DPP [Fig. 4 
(a)] and a just 0.34-fold of flux rate [Fig. 5 (b3) and Fig. 4 (b)].   
The dissolution and permeation measured for FFA and FFA cocrystals in the 
presence of PVP-VA were shown in Fig. 6. The dissolution of FFA cocrystals was 
significantly enhanced by PVP-VA. At a PVP-VA concentration of 200 µg/mL, a 
33.8% increase of DPP was observed for FFA-NIC and a 42.6% increase of DPP was 
observed for FFA-TP [Fig. 6 (a1) and Fig. 4 (a)]. At a PVP-VA concentration of 
16000 µg/mL, the DPP observed was increased to 460.5% for FFA-NIC and 409.4% 
for FFA-TP [Fig. 6 (a3) and Fig. 4 (a)]. However, the amount of FFA detected at the 
acceptor compartment seemed not to be proportional to the corresponding DPPs [Fig. 
6 (b3) and Fig. 4 (b)]. Actually, the FFA flux rate of FFA and FFA cocrystals were 
reduced with the increased concentration of PVP-VA. In spite of that, the FFA flux 
rates measured for FFA-NIC and FFA-TP at the PVP-VA concentration of 200 µg/mL 
or 4000 µg/mL were still higher than that measured for FFA in the absence of PVP-
VA [Fig. 4 (b)]. Whereas, when the added PVP-VA reached a concentration of 16000 
µg/mL the flux rate measured for FFA-NIC or FFA-TP was lower than that measured 
for FFA in the absence of PVP-VA [Fig. 4 (b)]. 
3.3. NMR Analysis of Interactions Between FFA, Coformers and Polymers. 
The 1H NMR experiments were conducted to investigate the interactions between 
FFA, coformers (NIC and TP) and polymers (PVP and PVP-VA) in solution, and the 
tests were summarized in Table S1 of the Supplementary Information. Assignments of 
the 1H chemical shifts of FFA, NIC, TP, PVP and PVP-VA were carried out 
previously.49, 53-57 The focus of this work was to examine the characteristic chemical 
shifts of the protons in each of the molecules of FFA, TP, and NIC. These shifts could 
be due to the hydrogen bonding or self-aggregation in solution, including i) the 
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chemical shifts of singlet peak of Hj and two doublet peaks of Hh in FFA; ii) the 
chemical shifts of Ha, Hb and Hc in NIC; and iii) the chemical shifts of Ha, Hb, Hc and 
Hd in TP. The detailed information regarding the protons in each molecule could be 
found in Table 1 and the full 1H NMR spectra of the experiments could be found in 
Fig. S1 of the Supplementary Information.  
3.3.1. 1H NMR Analysis of Single Component of FFA, NIC or TP. Fig. 7 (a) showed 
the 1H NMR chemical shifts of Hj and Hh in FFA and they seemed to be related to the 
concentrations of FFA. The existence of the hydrogen bond between the NHj group 
and the carbonyl O of the carboxylic acid within FFA had been well illustrated.54 
With an increased concentration, the self-association of FFA could also occur through 
the inter carboxylic acid hydrogen bondings, which was demonstrated by a downfield 
chemical shift of Hh from 8.049 ppm at 500 µg/mL to 8.061 ppm at 1000 µg/mL, and 
to 8.082 ppm at 5000 µg/mL. This could be due to proton deshielding by the 
hydrogen bonds, which the lengthening of the O-H bond reduced the valence electro 
density around the proton of Hh. The intermolecular association between the dimer of 
FFAs did not affect the molecular conformation in solution and the intramolecular N-
Hj···O=C was not disrupted.54 Therefore, at an increased concentration of FFA, the 
peaks of Hj displayed an upfield shift from 9.463 ppm at 500 µg/mL to 9.443 ppm at 
1000 µg/mL, and to 9.410 ppm at 5000 µg/mL. The self-association of NIC in 
solution occurred through inter-amide hydrogen bonding but not the stacking of the 
pyridine rings.58 Therefore, with an increased NIC concentration, the downfield shifts 
of Ha and Hb were observed. This was in contrast to Hc, whose spectra was almost 
constant (∆δ = 0.001 at 430 µg/mL and ∆δ = 0.005 at 2150 µg/mL) [Fig. 7(b)]. The 
self-association of TP occurred through the asymmetric dimer involving hydrogen 
bonding of Hb···O of C-CO-N-CHd  and C=N···HaN-C.59 Subsequently, all of the 1H 
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spectra  of Ha and Hb of TP moved to a lower field with an increased concentration, 
whereas the 1H chemical shifts of Hc and Hd remained constants (∆δ = 0.003 of Hc 
and ∆δ = 0.005 of Hd at 640 µg/mL and ∆δ = 0.013 of Hc and ∆δ = 0.020 of Hd at 
3200 µg/mL)  [Fig. 7(c)]. 
The 1H NMR chemical shifts of the polymer PVP or PVP-VA are shown in 
supporting information in Fig. S1, which were in the range from 4.000 ppm to 1.000 
ppm and did not overlap with the peaks of FFA, NIC/TP. Therefore the change of 
chemical shifts of FFA, NIC/TP in the presence of a polymer was caused by the 
interaction among molecules.  
3.3.2. 1H NMR Analysis of Binary Components. Samples of FFA, NIC and TP were 
analysed for 1H NMR in the presence of PVP or PVP-VA to identify their self-
association properties and their interactions with PVP or PVP-VA (Fig. 8).  The 
concentrations used were 1000 µg/mL for FFA, 430 µg/mL for NIC and 640 µg/mL 
for TP. 
In the presence of PVP or PVP-VA at a concentration of 200 µg/mL, the peaks of 
Hh in FFA had a downfield change, indicating the existence of hydrogen bonding 
between O-H of the carboxylic acid function group in FFA and the carbonyl O group 
in PVP or PVP-VA. As O=C of the carboxylic acid function group in FFA did not 
interact with PVP or PVP-VA, the intramolecular attraction of N-Hj···O=C in FFA 
was not disrupted. This was indicated by a constant spectra of Hj in FFA in the 
presence or absence of PVP or PVP-VA [Fig. 8 (a)]. When the concentration of PVP 
or PVP-VA was increased to 5000 µg/mL, the peaks of Hj and Hh in FFA moved in 
opposite directions: an upfield (shielding) shift for Hh and a down field shift for Hj. 
This suggested a different mechanism for the interactions between the FFA and the 
PVP or PVP-VA polymer. The upfield shift of Hh  might associate with the transition 
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of a solution environment from hydrophilic to hydrophobic as a result of the increased 
concentration of PVP/PVP-VA, leading to hydrophobic interactions between FFA and 
PVP/PVP-VA.57, 60 Obviously, the hydrophobic interaction would affect the 
conformation of FFA in solution, resulting in change of the intramolecular attraction 
of N-Hj···O=C and a consequent observation of the downfield shift of Hj. Furthermore, 
the broader 1H NMR peaks observed for FFA in solution containing PVP was in 
contrast to those observed in solution containing PVP-VA, indicating that PVP could 
significantly suppress the mobility of FFA molecules in comparison to PVP-VA. 
The peaks of NIC were not affected by PVP or PVP-VA at a concentration of 200 
µg/mL [Fig. 8 (b)], implying that there was no or weak interaction between NIC and 
PVP or PVP-VA. When the concentration of PVP or PVP-VA was increased to 5000 
µg/mL, the hydrogen bonding formed between NIC and PVP or PVP-VA was 
demonstrated as the downfield shifts of 1H NMR peaks of NIC. 
1H NMR spectra of TP were complex. It could be affected by the interactions 
between solute and solvent, solute and solute and solute and polymer. Moreover, 
dimerization of TP molecules was found to be the dominating factor that affected the 
1H chemical shifts of TP in CDCl3.59 TP was recognised as good proton donor and the 
dimers of TPs could be disrupted by PVP or PVP-VA in solution. This was proven by 
the downfield shifts of 1H NMR peaks of TP at a polymer concentration of 200 
µg/mL [Fig. 8 (c)]. Interestingly, further increased concentration of the polymers 
caused an upfield (shielding) shifts of Hb, Hd and Hc in TP.    
Within the structure of a solid crystalline FFA-NIC, the hydrogen bonds formed 
between two FFA and two NIC molecules. In detail, the Hi of amide acid in FFA 
formed hydrogen bond with the aromatic N of one of the NIC, and the carbonyl O 
atom of the acid of the same FFA formed another hydrogen bond with the amide Ha or 
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Hb of the other NIC.34 It was speculated that, as those formed in solid crystalline, the 
same interactions might form between FFA and NIC in CDCl3 solution. This was 
based on the facts of the deshielded chemical shifts of the Hh in FFA and the 
downfield Hc, Ha and Hb in NIC [Fig. 9 (a)]. As a result of the formation of hydrogen 
bond between the carbonyl O atom of the acid in FFA and NIC, the intramolecular 
attraction of N-Hj···O=C was disrupted and the chemical shift of Hj in FFA had a 
downfield movement. 
It was suggested that FFA and TP could  form a dimer through the Hi of amide acid 
in FFA and the aromatic N in TP.35 This was in consistent with the finding of the 
significant downfield chemical shift of the Hh in FFA [Fig. 9(b)]. Because the 
carbonyl O atom of the acid of FFA was not involved in the intermolecular interaction 
with TP, the intramolecular attraction of N-Hj···O=C of FFA was not disrupted, as 
shown by the constant spectra of Hj.  
3.3.3. 1H NMR Analysis of Ternary Components. 1H NMR spectra of the mixed 
samples of FFA, NIC/TP and PVP/PVP-VA were shown in Fig. 10. When the 
concentration of PVP was set to 200 µg/mL, the characteristic peaks of the Hh and Hj 
in FFA moved upfield, suggesting that, as a result of the interactions between the FFA 
and the PVP, the hydrogen bonds formed between the FFA and NIC were disrupted 
[Fig. 10 (a)]. In contrast, PVP-VA at 200 µg/mL had no effect on the spectra of the Hh 
and Hj in FFA, indicating that the interaction between the FFA and NIC played a 
dominant role over the interaction between the FFA and PVP-VA [Fig. 10 (b)]. 
Increasing PVP or PVP-VA to a concentration of 5000 µg/mL rendered the peaks of 
Hj and Hh moved to opposite directions [Fig. 10 (a) and Fig. 10-(b)]. This might 
reflect the dominant effect caused by the hydrophobic interaction between the FFA 
Page 19 of 44
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
and PVP or PVP-VA in comparison to the hydrogen bonds formed between the FFA, 
NIC and PVP or PVP-VA. 
When 200 µg/ml of PVP/PVP-VA was mixed with FFA and TP, the spectra of the 
Hh in FFA slightly moved upfield while that of the Hj almost had no change. It 
suggested that the hydrogen bonds formed between the FFA and TP were disturbed by 
the PVP or PVP-VA [Fig. 10 (c) and Fig. 10 (d)]. At a concentration of 5000 µg/mL, 
the PVP or PVP-VA rendered the peaks of the Hj and the Hh to opposite directions 
[Fig. 10 (c) and Fig. 10 (d)]. This was similar to those observed for the mixture of 
FFA and NIC and, once more, demonstrated the dominating hydrophobic interactions 
between the FFA and PVP or PVP-VA.  
4. DISCUSSION 
This research demonstrated that the supersaturated drug concentration generated by 
the cocrystal dissolution could be maintained through inclusion of a polymeric 
excipient in the formulation, for example, the supersaturated concentration of FFA 
generated by dissolution of FFA-NIC or FFA-TP was maintained by PVP or PVP-
VA[Fig. 4 (a)].4, 9, 10 On the other hand, in the presence of PVP or PVP-VA, the DPP 
detected for FFA-NIC or FFA-TP was proportional to the concentration of the 
polymers and it was much higher than that detected without PVP or PVP-VA [Fig. 4 
(a)]. However, as shown in the D/P system, an elevated concentration of FFA in the 
donor compartment was not accompanied by an increased flux rate of FFA to the 
acceptor compartment [Fig, 4 (b)]. This erratic drug permeation could lead to poor 
drug bioavailability, which was crucially related to the amount of drug molecules that 
could pass through the GI membrane. Therefore, it was important to explore the 
interplay of the solubility and permeability in the cocrystal based formulation, that 
enhanced solubility/dissolution might have positive, negative or no effect on the 
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subsequent permeability.18-20, 29 The mechanism of how a polymer affected the 
dissolution of the cocrystals had been investigated, and it seemed that the polymer 
could interact with the surface of the cocrystal to alter both the dissolution and 
precipitation.4 As a further investigation, this research revealed the interactions 
between the drug substance (FFA), the coformer (NIC or TP) and the polymer (PVP 
or PVP-VA) in solution and how these interactions maintain the supersaturated drug 
concentration and the subsequent permeation of the drug substance. 
Both PVP and PVP-VA are water soluble polymers. However, due to their 
structural difference (Table 1), the intermolecular interactions between PVP/PVP-VA 
and the drug substance FFA or coformer (NIC or TP) were different. This could affect 
not only the nucleation and growth kinetics9 but also the permeation of FFA in 
solution [Fig. 4 (b)]. Interestingly, at the same concentration, PVP-VA always 
rendered a higher DPP for FFA-NIC and FFA-TP than PVP [Fig. 4(a)]. In contrary, 
the effect of PVP-VA on the flux rate of FFA-NIC or FFA-TP could be greater or 
smaller than PVP, which was seemingly concentration dependent (Fig. 4). In fact, for 
FFA-NIC and FFA-TP, while the FFA flux rates and DPPs measured were in 
proportion to the concentration of PVP, the FFA flux rates measured were in contrast 
to the DPPs in the presence of PVP-VA (Fig. 4). Therefore, it was essential to take 
into account both the flux rate and DPP when evaluating a cocrystal based 
formulation.      
Based on the results in Fig.2, PVP could act as a stabilizing agent in the formulation 
as the equilibrium solubility of FFA was not increased significantly across the whole 
range of the concentrations of PVP. The hydrogen bonds between FFA and PVP 
should be the dominant force when the concentration of PVP was below 4000 µg/mL, 
which was confirmed by the downfield chemical shifts of Hh in FFA [Fig. 8 (a)]. The 
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flux rate was determined by the degree of supersaturation (ratio of dissolved amount 
of unchanged API to its thermodynamic solubility), which was the driving force for 
transporting the drug substance across the membrane.29 PVP might inhibit the 
nucleation of FFA to maintain its supersaturated concentration [Fig. 5 (a)]9 and to 
increase the flux rate of FFA across the regenerated cellulose membrane [Fig.5 (b)].29 
Due to the bulk precipitation dissolution mechanism, the higher supersaturation 
concentration of FFA generated by FFA-TP led to a higher flux rate in comparison to 
FFA-NIC.4  
When the concentration of PVP was above 4000 µg/mL, the attraction between 
FFA and PVP changed into hydrophobic interaction due to the confined spaces 
between the FFA and PVP molecules. This was confirmed by the upfield chemical 
shifts of Hh in FFA [Fig. 8 (a)]. It must be stressed that, at such a concentration, 
micellization of PVP did not occur due to its rigorous backbone structure and, 
therefore, PVP had no significant effect on the equilibrium solubility of FFA (Fig. 2). 
Consequently, the mobility of FFA in solution was seen to reduce with the increased 
concentration of PVP, as illustrated by the broaden peak of the Hj in FFA [Fig. 8 (a)].  
The reduced flux rate of FFA at a PVP concentration of 16000 µg/mL [Fig. 4 (b)] 
was the result of a combined effects of the reduced dissolution of the cocrystals [Fig. 
5 (a)] and the reduced solute activity coefficient.37 Although the interaction between 
FFA and PVP was disturbed by the interaction between PVP and the coformers (Fig. 
9 and Fig. 10), the role of PVP as a stabilizing agent did not change, as demonstrated 
by the minor change of FFA solubility with or without the presence of the coformers 
(Fig. 2). As a consequence, the flux rate of FFA solely depended on the DPP of the 
cocrystals, which the maximal flux rate of FFA was observed for FFA-TP in the 
presence of 4000 µg/mL of PVP.  
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As seen in Fig.2, PVP-VA had a transitional role in the cocrystal formulation, 
depending on its concentrations. At a concentration of up to 1000 µg/mL and the 
absence of NIC or TP, PVP-VA acted as a stabilizing agent as it had no effect on the 
equilibrium solubility of FFA (Fig. 2). The downfield shifts of the Hh in FFA 
indicated the formation of hydrogen bond between the FFA and the PVP-VA [Fig. 8 
(a)]. Compared to PVP, PVP-VA was more hydrophobic and flexible, leading to 
micellization at a higher concentration.61 This research set the critical micelle 
concentration (CMC) of PVP-VA at 4000 µg/mL. Therefore, at a concentration over 
the CMC, PVP-VA significantly increased the solubility of FFA. The 1H NMR 
spectra of FFA showed the upfield shifts of the Hh at PVP-VA concentration of 5000 
µg/mL [Fig. 8 (a)], from which the conclusion could be drawn that the encapsulation 
of FFA took place in PVP-VA micelles. In other words, the role of PVP-VA changed 
to a solubilisation agent in the formulation.  
In the presence of NIC or TP, PVP-VA demonstrated a significant solubilisation 
capacity (Fig. 2). It was likely that the association of PVP-VA with a coformer , as 
shown in Fig. 8 (b) and Fig. 8(c),  provided an expanded region of the inner core for 
drug solubilization.62 The CMC of PVP-VA reduced significantly around 200 µg/mL, 
at which point the equilibrium solubility of FFA started to increase (Fig. 2). Taken 
together, it seemed that PVP-VA behaved as a solubilisation agent in the cocrystal 
formulations regardless of its concentrations.  
Corresponding to the increased equilibrium solubility of FFA, the DPPs of the FFA 
cocrystals were proportional to the concentration of PVP-VA [Fig. 4 (a)]. From the 
perspective of thermodynamics, an elevated drug concentration due to the presence of 
PVP-VA was fundamentally different from the drug supersaturation generated by the 
stabilizing agent of PVP. Solubilizing agent, such as PVP-VA, affected the 
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concentrations by increasing the equilibrium solubility rather than increasing the 
chemical potential (degree of supersaturation), as shown by the reduced flux rate of 
FFA across the membrane [Fig. 4 (b)]. This was in consistent with the findings from 
previous studies.18-20, 29  
Overall, the permeation of a FFA cocrystal could be affected by a series of factors, 
such as the types of polymers, the concentrations of the polymers and coformers. In 
particular, the interactions between the polymer and the coformer might play roles in 
improving the absorption of the drug substance.  
5. CONCLUSION 
The dissolution and permeation of the cocrystals, FFA-NIC and FFA-TP, in the 
presence of polymers, PVP and PVP-VA, were examined using a 
dissolution/permeation (D/P) system. It showed that the types of polymers, their 
concentrations and interactions with coformers were the determining factors. The role 
of PVP as a stabilizing agent was not altered in spite of its interactions with the 
coformers of NIC and TP, which was supported by the fact that the flux rate of FFA 
solely depended on the DPP of the cocrystals. With an appropriate PVP concentration, 
the maximal flux rate of FFA could be obtained for a given FFA cocrystal. The role of 
PVP-VA could change due to its association with the coformers, such as from a 
stabilizing agent to a solubilisation agent. It was also found that PVP-VA rendered the 
measurement of flux rate contrasting to the measurement of the corresponding DPP. 
The maximal flux rate of FFA could only be obtained at a very low concentration of 
PVP-VA. At last, 1H NMR provided evidence regarding the molecular interactions 
between the FFA, the coformers and the polymers at the atomic level. In conclusion, 
understanding the relationships between the drug substance, coformers and polymers 
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at molecular level was the key to optimise the solubility and permeability to maximize 
the performance of cocrystal based oral drug products.   
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Table 1. Molecular structures of FFA, coformers (NIC and TP), FFA cocrystals 
(FFA-NIC and FFA-TP) and polymers (PVP and PVP-VA). 
FFA 
 
NIC  
 
TP 
 
FFA-
NIC 
 
FFA-
TP 
 
PVP 
 
PVP-
VA 
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Table 2. HPLC methods 
 Mobile phase Flow rate 
(mL/min) 
Detection wavelength 
(nm) 
FFA 14.5% water (with 0.5% formic 
acid), 85% methanol 
1.5  286 
NIC 10% methanol, 90% water 1 265 
TP 40% methanol, 60% water 1 265 
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Figure 1. Diagram of the dissolution/permeation (D/P) system. 
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Figure 2. Effect of polymer and/or conformer on the equilibrium solubility of FFA. 
The apparent equilibrium solubility of FFA were measured in 0.01 M PBS (pH 4.5) 
with or without PVP or PVP-VA. The concentrations of NIC or TP used were 47.8 
µg/mL and 71.1 µg/mL. 
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Figure 3. The dissolution (a) and permeation (b) of the FFA, FFA-NIC and FFA-TP 
were measured using the dissolution/permeation (D/P) system. The solvent used was 
0.01 M PBS. 
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Figure 4. The D/P system was used for the DPP and flux rate measurement for FFA, 
FFA-NIC and FFA-TP. The donor compartment was filled with 0.01 M PBS (pH 4.5) 
containing either PVP or PVP-VA at concentrations of 200 µg/mL, 4000 µg/mL or 
16000 µg/mL, and the receptor compartment was filled with 0.01 M PBS (pH 4.5). 
 
(a) 
 
(b) 
 
  
-30
20
70
120
170
220
270
320
370
420
470
520
570
PBS PVP
200ug/mL
PVP
4000ug/mL
PVP
16000ug/mL
PVP-VA
200ug/mL
PVP-VA
4000ug/mL
PVP-VA
16000ug/mL
D
P
P
 (
%
)
Donor cell
FFA FFA-NIC FFA-TP
0
0.01
0.02
0.03
0.04
0.05
0.06
PBS PVP
200ug/mL
PVP
4000ug/mL
PVP
16000ug/mL
PVP-VA
200ug/mL
PVP-VA
4000ug/mL
PVP-VA
16000ug/mL
F
lu
x
 r
a
te
 (
u
g
/(
cm
^
2
*
m
in
))
Acceptor  cell
FFA FFA-NIC FFA-TP
Page 36 of 44
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
Figure 5. The dissolution and permeation of FFA, FFA-NIC and FFA-TP were 
investigated using the D/P system. The donor compartment was filled with 0.01 M 
PBS (pH 4.5) containing PVP at concentrations of 200 µg/mL, 4000 µg/mL or 16000 
µg/mL, and the receptor compartment was filled with 0.01 M PBS (pH 4.5). 
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Figure 6. The dissolution and permeation of FFA, FFA-NIC and FFA-TP were 
investigated using the D/P system. The donor compartment was filled with 0.01 M 
PBS (pH 4.5) containing PVP-VA at concentrations of 200 µg/mL, 4000 µg/mL or 
16000 µg/mL, and the receptor compartment was filled with 0.01 M PBS (pH 4.5). 
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Figure 4. 1H NMR spectra of FFA, NIC and TP. Samples of FFA (500 µg/mL, 1000 
µg/mL and 5000 µg/mL), NIC (215 µg/mL, 430 µg/mL and 2150 µg/mL) and TP 
(320 µg/mL, 640 µg/mL and 3200 µg/mL) were prepared in deuterated chloroform 
(CDCl3) using the standard 5 mm NMR tubes and the spectrum of tetramethysilane 
(TMS) was used as an internal standard. 
 
(a) FFA 
 
(b) NIC 
 
 
(c) TP 
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Figure 5. Effect of PVP or PVP-VA on the 1H NMR spectra of FFA, NIC and TP. 
Samples of FFA (1000 µg/mL), NIC (430 µg/mL) and TP (640 µg/mL) were prepared 
in deuterated chloroform (CDCl3) using the standard 5 mm NMR tubes and the 
spectrum of tetramethysilane (TMS) was used as an internal standard. PVP or PVP-
VA was included in the solution of CDCl3 at a concentration of 200 µg/mL or 5000 
µg/mL.   
(a) FFA 
 
(b) NIC 
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Figure 6. 1H NMR spectra of mixture FFA with NIC or TP. Samples were prepared in 
deuterated chloroform (CDCl3) using the standard 5 mm NMR tubes and the spectrum 
of tetramethysilane (TMS) was used as an internal standard. The FFA and its 
coformers were included in the CDCl3 solution at 1:1 molar ratio. The concentration 
of FFA, NIC and TP were 1000 µg/mL, 430 µg/mL, and 640 µg/mL. 
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Figure 7. Effect of PVP or PVP-VA on the 1H NMR spectra of mixed FFA with NIC or 
TP.1H NMR spectra of FFA in an equal molar mixture of FFA and NIC or TP at difference 
concentrations of a polymer in CDCl3. Samples were prepared in deuterated chloroform 
(CDCl3) using the standard 5 mm NMR tubes and the spectrum of tetramethysilane (TMS) 
was used as an internal standard. The FFA and its coformers were included in the CDCl3 
solution at 1:1 molar ratio to obtain the concentrations of 430 µg/mL of NIC, 640 µg/mL of 
TP and 1000 µg/mL of FFA. PVP or PVP-VA was included in the solution of CDCl3 at a 
concentration of 200 µg/mL or 5000 µg/mL. 
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(d) PVP-VA 
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